Skip to main content Skip to footer

New Science: A new economic reality for growth

May 25, 2021


In brief

How do you lead amidst change?

What if you could find opportunities to tie profitability to improvements in patients’ health, rewarding the innovation and better outcomes from New Science?

New Science is more important than ever

Scientific innovation drives biopharma and as science has changed, so has the way we innovate. The way we measure benefits will now shape the future.

A new economic reality challenges profitability

It is no longer sustainable to pass increased costs to consumers. Biopharma’s feel pressure from governments, people and payers to reduce costs.

Success requires a future fit enterprise

In light of this new economic environment, the biopharma industry needs to consider a shift in how it creates, captures and shares value.

1. New Science is more important than ever


New Science is projected to drive 81% of biopharma revenue growth and 61% of all revenues between 2021 and 2026, outpacing our previous forecast of 54% of all revenues from 2017-2022.


expected higher average net present value (NPV) for New Science treatments versus traditional counterparts from 2022-2026.


of all new deals intended to create new therapies in the last 5 years involved New Science treatments.

2. A new economic reality challenges profitability

1. People can’t afford it

In the US, the average premium for family coverage has increased 22% over the last five years and 55% over the last ten years.

2. Governments struggle to manage costs

Healthcare spending reached nearly $4 trillion in 2019, more than 17% of US GDP accounting for 24% of government spending.

3. Payers feel the pain

Increased focus on financial consideration causes friction between pharmacy benefit managers, payers, HCPs and patients.

3. Success requires a future-fit enterprise to address both sides of the profitability equation

Addressing the profitability equation

Data-led drug discovery

Primarily influenced by advanced biomarker discovery capabilities with deep learning and multi-modal models.

Efficiencies of New Science

Include a greater likelihood of success, smaller patient cohorts, and overall genomic efficiencies.

Virtual, hybrid and decentralized clinical trials

Leverage in silico and digital twin capabilities to enable near-to-patient trials using digital technology.

Regulatory innovation

Creates opportunities to leverage more efficient protocols and new ways to balance safety/risk profiles.

Virtualized selling

Will bring savings along with removing excess from sales forces.

Closing thoughts

Meet the team

Petra Jantzer, Ph.D.

Senior Managing Director – Global Life Sciences Lead

Aman Bajaaj

Managing Director – Asia Pacific Life Sciences Lead

Brad Michel

Managing Director – Life Sciences Lead, North America

Ramon Pressburger

Managing Director – North America Lead and Strategy Lead, Global Life Sciences

Elizabeth Ferguson-LaChance

Senior Manager – Life Sciences, Business Strategy

Selen Karaca-Griffin

Senior Principal – Life Sciences, Research Global Lead
Visit our Subscription and Preference Center